Unlocking a New Era in Migraine Prevention: Dr. Nada Hindiyeh on CGRP Monoclonal Antibodies
We’re excited to share that Dr. Nada Hindiyeh, Chief Medical Officer at Haven Headache & Migraine Center, appears in a new expert-led discussion with Dr. Susan Hutchinson on the science and clinical use of CGRP monoclonal antibodies (mAbs) for migraine prevention.
In this clinical education session, the two headache specialists cover:
- What CGRP is and how it relates to migraine
- How monoclonal antibodies work to prevent attacks
- Who benefits most from this class of medications
- Key clinical trial data and patient case examples
CGRP mAbs represent one of the most meaningful shifts in migraine care in decades—offering preventive relief with fewer side effects than traditional options.
At Haven, these therapies are part of our personalized approach for people living with frequent or disabling migraine. We help patients access these treatments through insurance, track their progress, and adjust care plans as needed.
If you're curious about the latest in preventive migraine care, this video is an excellent place to start.
Book a visit with a Haven specialist to see if CGRP mAbs could be right for you.